Navigation Links
Deliver siRNAs Into Primary Cells

siPORT siRNA Electroporation Kit
Deliver siRNA into primary cells, cells grown in suspension, and other difficult-to-transfect cells

Maintain high cell viability under a wide range of conditions

Optimize electroporation of your cells quickly with included positive and negative controls


Primary cells serve as an important model system for gene function analysis, target validation, and drug discovery since they are more similar to their in vivo counterparts than are immortalized cells. However, delivery of siRNA into these cells has proven to be a challenge. Efficient transfer of siRNA into primary cells by chemical transfection (e.g. using lipid-based reagents) works with only a few cell types [1]. Ambion's new siPORT siRNA Electroporation Buffer overcomes this problem. It can be used with commonly available electroporators to ensure highly efficient siRNA delivery into many different cell types, including primary cells, while maintaining high levels of cell viability [2].

Now, Ambion introduces the siPORT siRNA Electroporation Kit, which provides a Cy3-labeled siRNA Control, and positive (GAPDH) and negative (non-targeting) siRNA controls in addition to the siPORT siRNA Electroporation Buffer. The kit makes it easy to optimize electroporation conditions for any cell type. For instance, successful delivery of siRNA into cells by electroporation depends on several critical parameters: voltage, pulse length, number of pulses, and siRNA concentration. The Cy3-labeled control siRNA makes it simple to monitor the uptake of siRNA into the target cells by fluorescence microscopy. The siPORT siRNA Electroporation Kit provides the means to dramatically simplify and speed up the electroporation optimization process, because a well-characterized siRNA targeting GAPDH and a widely used negative control siRNA and detailed optimization instructions are also included.


A Complete System for Optimization of siRNA Delivery

As seen in Figure 1, electroporation was used to deliver Cy3-labeled siRNA into human primary mesenchymal stem cells (hMSC) and rat neuronal pheochromocytoma (PC-12) cells. Almost every cell (>90%) contained detectable amounts of Cy3-labeled siRNA 24 hours after electroporation. This is a useful preliminary experiment to quickly screen multiple transfection conditions when working with new cell lines. A Cy3-labeled negative control siRNA comes with the kit for this purpose.

Figure 1. Electroporation of Primary Cells and Hard-to-transfect Neuronal Cells. A Cy3-labeled GAPDH siRNA (1.5 g) was added to primary Human Mesenchymal Stem Cells (hMSC) or rat neuronal pheochromocytoma (PC-12) cells in siPORT Electroporation Buffer (75 l) and electroporated using hMSC-specific or PC-12-specific parameters. Cells were fixed 24 hours after electroporation, stained with DAPI (blue), and analyzed by fluorescence microscopy (Cy3 fluorescence; red).


Because knockdown of gene expression in some cell types may not correlate 100% with uptake of fluorescently labeled siRNA, the siPORT siRNA Electroporation Kit also includes a positive control siRNA that targets GAPDH. The unlabeled GAPDH siRNA control can be used in conjunction with the unlabeled negative control siRNA (also included) to refine electroporation conditions by monitoring knockdown of GAPDH mRNA levels. The negative control siRNA is important not only for optimization experiments, but also for any siRNA experiment to confirm the absence of nonspecific effects due to transfection.

The siPORT siRNA Electroporation Kit has been tested with two commonly used single-cuvette electro-pulse generators: Gene Pulser Xcell (Bio-Rad) and ECM 830 (BTX). Their performance was similar when the same electroporation parameters were used.


Effective Silencing in Primary Cells

Figure 2 shows gene silencing induced by several different siRNAs, all delivered into hMSC and NHDF-neo cells (both are primary cells: human mesenchymal stem cells, and normal human dermal fibroblasts-neonatal) by electroporation using siPORT siRNA Electroporation Buffer. A critical parameter in the success of any RNAi experiment is the potency and specificity of siRNA sequences. To ensure the success of these gene-silencing experiments we used Silencer Pre-designed siRNAs. These siRNAs are designed using an extensively tested algorithm developed by Cenix BioScience, and have been shown to be highly effective at silencing target genes. As seen in Figure 2, 48 hours after transfection, mRNA expression levels of the targeted genes were reduced by 70% or more for all siRNAs tested in both cell types.

Figure 2. siRNAs Electroporated into hMSC and NHDF-neo Cells. Six siRNAs (1.5 g) targeting CDK2, JAK1, p53, GAPDH, uPAR, PKR, as well as a negative control siRNA, were electroporated into hMSC cells (A). Seven siRNAs (1.5 g) targeting Cyclin D1, NFκBp65, STAT1, PKCα, JAK1, RAF1, MMP-2, and a negative control siRNA were individually electroporated into NHDF-neo cells (B). All electroporations were conducted using the siPORT siRNA Electroporation Kit. 48 hours after electroporation, the cells were harvested and analyzed by real-time RT-PCR for corresponding gene expression levels. 18S rRNA levels were used to normalize the expression data. Percent remaining gene expression was calculated as a percentage of target mRNA compared with target mRNA from cells electroporated with the negative control siRNA.


Effective Gene Silencing in Primary and Difficult-to-Transfect Cells

In Figure 3, several different cell types were electroporated with the GAPDH control siRNA using individually optimized electroporation conditions. 48 hours after electroporation, GAPDH mRNA levels were reduced by 70% or more in each cell type. Cell viability of 70% or greater was maintained (Figure 3). Ambion scientists have optimized electroporation conditions for many different cell types. These electroporation conditions are available on our Electroporation Buffer webpage (see uppermost data table on right side of page).

Figure 3. Cell Viability and Reduction of GAPDH Gene Expression in Several Cell Types. Successful gene silencing and high cell viability was achieved in 11 primary cell types and 3 hard-to-transfect immortalized cell lines: Primary Cells: human mesenchymal stem cells (hMSC), normal human astrocyte cells (NHA), normal human dermal fibroblasts-neonatal (NHDF-Neo), rat astrocytes (DI TNC1), normal human umbilical vein endothelial cells (HUVEC), bovine aortic endothelial cells (BAEC), bovine aortic vascular smooth muscle cells (BAVSMC), bovine adrenal microvascular endothelial cells (BAMEC), mouse embryo fibroblast (MEF), rhesus monkey stem cells (RMSC), bovine lung microvascular endothelial cells (BLMVEC) are shown in blue. Hard-to-transfect cell lines: Jurkat (human acute T-cells), K562 (human erythroleukemia cells), PC12 (rat pheochromocytoma cells) are shown in black.

siRNA targeting GAPDH or a negative control siRNA (1.5 g) were electroporated. 48 hours after transfection, the cells were harvested and analyzed by real time RT-PCR for gene expression levels. 18S rRNA levels were used to normalize GAPDH expression. Remaining gene expression was calculated as a percentage of gene expression compared with the negative control siRNA.


Summary
Ambion's siPORT siRNA Electroporation Kit provides a streamlined protocol, with the necessary reagents for delivering siRNAs into multiple cell types. Because some biologically important cell types are refractory to other methods of transfection, electroporation can greatly simplify siRNA studies in these cell lines.


Scientific Contributors
Dmitriy Ovcharenko, Po-Tsan Ku, Kevin Kelnar, Nitin Puri Ambion, Inc.


back to top


Ordering Information
Cat# Product Name Size 1629 siPORT siRNA Electroporation Kit 60 rxns 8990 siPORT siRNA Electroporation Buffer 12 x 1.5 ml
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
2. High-Titer Retroviral Vectors for Gene Delivery
3. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
4. A New Way to Assess siRNA Delivery Efficiency
5. Delivering siRNA Using Adenoviral Vectors
6. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
7. Delivering siRNAs to Difficult Cell Types
8. Enhanced siRNA Delivery and Long-term Gene Silencing
9. High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells
10. Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice
11. Silencer Validated siRNAs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Deliver siRNAs Into Primary Cells

(Date:8/28/2015)... Research and Markets ( ... "Global & USA BioSimilar Market Analysis to 2021" ... US Biosimilar market will be initiated in September as ... will the global market react? Will biosimilars explode into ... save the US economy up to $250 billion within ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... , ... Capital Edge Consulting , a nationwide consulting firm that specializes ... ranking as one of the top 5000 companies listed on the 2015 Inc. ... , “It is truly an honor to be recognized as one of America’s fastest ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that executives from ... the month of September.  , ... Rodman & Renshaw,s 17th Annual Global Investment Conference on ... the St. Regis Hotel in New York ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... Pharmos Corporation,(Nasdaq: PARS ) today reported results for the ... loss of $2.7 million, or $0.10 per share,for the second ... or,$0.18 per share, in the second quarter 2007. Cash and ... decrease in net loss for the second quarter 2008 is ...
... Aug. 7 Anesiva,Inc. (Nasdaq: ANSV ) today ... six months ended June 30, 2008., "The 2008 ... we,introduced Zingo(TM) in the U.S. pediatric hospital market," said ... I,m pleased,to report that our Phase 3 trials of ...
... announced that it,has extended its current offer to purchase ... Purchase Warrants, Class 1 and Class B Common Stock,Purchase ... time, on,Friday, August 15, 2008. The offer was scheduled ... August 7, 2008., The extension will provide Warrant ...
Cached Biology Technology:Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... 2015 The latest 364 page report ... of the global border security market . Visiongain ... in 2015. Now: Border security is hard to ... the business critical issue you need to know about - ... objective analysis of how this will impact your company and ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... protein regulates secretion levels in the fruit fly's salivary ... the May 15 issue of Development, the finding improves ... is a critical ability of certain glands and cell ... researchers discovered that a protein called CrebA single-handedly controls ...
... skin cancer, researchers at the Huntsman Cancer Institute at the ... gene found in up to 30 percent of human tumors. ... in cell signaling, or communication among cells. When mutated, however, ... shown to promote the growth of cancers in the pancreas, ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
Cached Biology News:Study: Well-known protein helps stem cells become secretory cells 2Scientists inhibit cancer gene 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: